19.10+0.02+0.10%
After-market 04:49:28 PM EDT 6/12/2024BTT
Plus500. 81% of retail CFD accounts lose money
19.08+0.30+1.60%
Official Close 03:59:59 PM EDT 6/12/2024BTT
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
On Tuesday 06/11/2024 the closing price of the Cassava Sciences share was $19.08 on BTT.Compared to the opening price on Tuesday 06/11/2024 on BTT of $19.22, this is a drop of 0.73%.Cassava Sciences's market capitalization is $901.60 M by 47.98 M shares outstanding.
Is Cassava Sciences stock a Buy, Sell or Hold?
Cassava Sciences stock has received a consensus rating of buy. The average rating score is and is based on 7 buy ratings, 0 hold ratings, and 0 sell ratings.What was the 52-week low for Cassava Sciences stock?
The low in the last 52 weeks of Cassava Sciences stock was 8.38. According to the current price, Cassava Sciences is 227.92% away from the 52-week low.What was the 52-week high for Cassava Sciences stock?
The high in the last 52 weeks of Cassava Sciences stock was 32.05. According to the current price, Cassava Sciences is 59.59% away from the 52-week high.What are analysts forecasts for Cassava Sciences stock?
The 7 analysts offering price forecasts for Cassava Sciences have a median target of 125.00, with a high estimate of 131.00 and a low estimate of 124.00. The median estimate represents a 15.28 difference from the last price of 19.10.Cassava Sciences Stock Snapshot
19.06
Bid
8.00
Bid Size
19.11
Ask
6/12/2024
Date
4:49 PM
Time
33,206.00
Volume
19.08
Prev. Close
19.22
Open
918.72 M
Market Cap in USD
47.98 M
Number of Shares
18.87
Day Low
19.74
Day High
19.10
8.38
52 Week Low
32.05
52 Week High
19.10
0.00
Dividend in USD
0.00
Dividend Yield
93.60
Free Float in %
-2.32
EPS in USD
3.25
Book Value per Share in USD
-1.96
Cash Flow per Share in USD
Cassava Sciences NewsMore News
TipRanks
Analysts Offer Insights on Healthcare Companies: Aroa Biosurgery Ltd (AU:ARX), Cassava Sciences (SAVA) and Amplifon S.p.A. (GB:0N61)
Zacks
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
TipRanks
Cassava Sciences Progresses in Phase 3 Trials, Secures Strong Cash Position: A Buy Rating Justified
InvestorPlace
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024
Historical Prices for Cassava Sciences
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Cassava Sciences Analyst Data
Total Analysts: 7
Buy Ratings: 7 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 124.00 Median: 125.00 Highest: 131.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Cassava Sciences Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/17/24 | H.C. Wainwright & Co. | Maintained Buy | $131 | gut | ||
| 03/05/24 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut | ||
| 08/08/23 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut | ||
| 07/06/23 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut | ||
| 05/09/23 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut | ||
| 03/06/23 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut | ||
| 01/24/23 | H.C. Wainwright & Co. | Maintained Buy | $124 | gut |
Cassava Sciences Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 0 | 100 | 0 | 6 | 72 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | -1.07 | 0.36 | -1.20 | -0.76 | 0.26 |
| P/E Ratio | -17.50 | 52.17 | -15.65 | -24.71 | 72.23 |
| EBIT | -89 | -20 | -120 | -106 | -34 |
| EBITDA | - | - | - | - | - |
| Net Profit | -37 | 18 | -67 | -43 | 15 |
| Net Profit Adjusted | -86 | 85 | - | - | - |
| Pre-Tax Profit | -37 | 31 | -67 | -53 | 19 |
| Net Profit (Adjusted) | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
| EPS (GAAP) | -0.65 | -0.91 | -1.20 | -0.76 | 0.26 |
| Gross Income | 200 | 200 | 369 | - | - |
| Cash Flow from Investing | 0 | 0 | - | - | - |
| Cash Flow from Operations | -191 | -48 | - | - | - |
| Cash Flow from Financing | 210 | 0 | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | -34 | -48 | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | - | - | - | - | - |
| Net Debt | - | - | - | - | - |
| Research & Development Exp. | 73 | 94 | 72 | 61 | 43 |
| Capital Expenditure | 0 | 0 | - | - | - |
| Selling, General & Admin. Exp. | 15 | 32 | 48 | 50 | 53 |
| Shareholder’s Equity | 316 | 532 | - | - | - |
| Total Assets | 318 | 534 | - | - | - |
| Previous Quarter ending 03/31/24 | Current Quarter ending 06/30/24 | Next Quarter ending 09/30/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 2 | 3 | 3 | 3 | 2 |
| Average Estimate | -0.460 USD | -0.407 USD | -0.417 USD | -1.073 USD | 0.360 USD |
| Year Ago | -0.580 USD | -0.630 USD | -0.610 USD | -2.320 USD | -1.073 USD |
| Publish Date | 5/10/2024 | 7/31/2024 | 11/5/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 2 | 3 | 3 | 3 | 2 |
| Average Estimate | 0 USD | 0 USD | 0 USD | 0 USD | 100 USD |
| Year Ago | - | - | - | - | 0 USD |
| Publish Date | 5/10/2024 | 7/31/2024 | 11/5/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change of sales in % | - | - | - | - | - | - | - |
| Gross profit on sales | -1.53 | -1.30 | -0.53 | -0.02 | -0.06 | -0.07 | -0.07 |
| Gross profit on sales change in % | -17.60 | -143.63 | -2,327.27 | 62.07 | 15.94 | -1.47 | -17.24 |
| Operating income | -105.96 | -80.92 | -36.77 | -11.03 | -9.69 | -6.66 | -11.95 |
| Operating income change in % | -30.94 | -120.08 | -233.32 | -13.86 | -45.42 | 44.25 | 20.11 |
| Income before tax | -97.22 | -76.25 | -32.39 | -6.33 | -4.63 | -6.56 | -11.91 |
| Income before tax change in % | -27.50 | -135.44 | -411.29 | -36.77 | 29.37 | 44.95 | 19.79 |
| Income after tax | -97.22 | -76.25 | -32.39 | -6.33 | -4.63 | -6.56 | -11.91 |
| Income after tax change in % | -27.50 | -135.44 | -411.29 | -36.77 | 29.37 | 44.95 | 19.79 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 14.20 | 7.30 | 12.87 | 2.10 | 1.39 | 0.51 | 1.13 |
| Long-term liabilities per share | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Equity | 137.47 | 227.54 | 253.92 | 92.20 | 22.10 | 19.63 | 9.70 |
| Equity change in % | -39.58 | -10.39 | 175.40 | 317.21 | 12.59 | 102.37 | -47.96 |
| Balance sheet total | 151.66 | 234.83 | 266.78 | 94.30 | 23.49 | 20.14 | 10.83 |
| Balance sheet total change in % | -35.42 | -11.98 | 182.91 | 301.52 | 16.62 | 85.94 | -43.89 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - | - | - | - |
| P/E ratio (ear end quote, diluted EPS) | - | - | - | - | - | - | - |
| P/E ratio (year end quote) | - | - | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 90.64 | 96.89 | 95.18 | 97.77 | 94.09 | 97.46 | 89.55 |
| Debt ratio in % | 9.36 | 3.11 | 4.82 | 2.23 | 5.91 | 2.54 | 10.45 |
Cassava Sciences Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| ROBERTSON SANFORD | 04/25/2024 | 69,000.00 | 955,851.00 | 22.00 | Buy | No |
| Barry Richard | 04/22/2024 | 176,085.00 | 469,562.00 | 22.00 | Buy | No |
| Kupiec James William | 04/17/2024 | 1,500.00 | 4,000.00 | 22.00 | Buy | No |
| Schoen Eric | 04/16/2024 | 1,500.00 | 21,300.00 | 22.00 | Buy | No |
| ROBERTSON SANFORD | 08/22/2023 | 30,000.00 | 886,851.00 | 17.45 | Buy | No |
| Barry Richard | 08/21/2023 | 16,571.00 | 293,477.00 | 16.65 | Buy | No |
| Barry Richard | 08/20/2023 | 1,906.00 | 276,906.00 | 16.80 | Buy | No |
| SCANNON PATRICK J MD PHD | 06/11/2023 | 1,000.00 | 1,000.00 | 0.95 | Buy | No |
| BARBIER REMI | 05/23/2023 | 47,723.00 | 734,279.00 | 25.25 | Sell | No |
| BARBIER REMI | 05/23/2023 | 9,545.00 | 380,852.00 | 25.25 | Sell | No |
| BARBIER REMI | 05/23/2023 | 71,428.00 | 782,002.00 | 16.87 | Buy | No |
| BARBIER REMI | 05/23/2023 | 14,285.00 | 390,397.00 | 16.87 | Buy | No |
| ROBERTSON SANFORD | 05/09/2023 | 2,142.00 | 856,851.00 | 16.66 | Buy | No |
| ROBERTSON SANFORD | 05/09/2023 | 3,571.00 | 854,709.00 | 16.66 | Buy | No |
| ROBERTSON SANFORD | 05/09/2023 | 3,571.00 | 851,138.00 | 19.60 | Buy | No |
| GUSSIN ROBERT Z | 04/30/2023 | 7,077.00 | 10,617.00 | 23.34 | Buy | No |
| GUSSIN ROBERT Z | 04/30/2023 | 3,571.00 | 17,694.00 | 19.60 | Buy | No |
| GUSSIN ROBERT Z | 04/30/2023 | 3,571.00 | 14,123.00 | 16.66 | Buy | No |
| GUSSIN ROBERT Z | 04/30/2023 | 2,142.00 | 10,552.00 | 16.66 | Buy | No |
| O DONNELL MICHAEL J | 03/06/2023 | 2,778.00 | 6,873.00 | 25.20 | Sell | No |
| O DONNELL MICHAEL J | 03/06/2023 | 2,361.00 | 9,651.00 | 25.20 | Sell | No |
| O DONNELL MICHAEL J | 03/06/2023 | 3,571.00 | 12,012.00 | 19.60 | Buy | No |
| O DONNELL MICHAEL J | 03/06/2023 | 3,571.00 | 8,441.00 | 16.66 | Buy | No |
| Barry Richard | 03/06/2023 | 77,276.00 | 275,000.00 | 25.76 | Buy | No |
| Barry Richard | 03/05/2023 | 11,565.00 | 197,724.00 | 26.13 | Buy | No |
Cassava Sciences Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2022 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2021 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2020 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2019 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2018 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2017 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2016 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2015 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2014 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2013 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2012 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2011 | Cassava Sciences | 0.00 | 0.00 | USD |
| 2010 | Cassava Sciences | 14.00 | 29.63 | USD |
| 2009 | Cassava Sciences | 0.00 | 0.00 | USD |
*Yield of the Respective Date
Cassava Sciences Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | -0.407 USD | Q2 2024 Earnings Release | 07/31/2024 |
| Earnings Report | -0.417 USD | Q3 2024 Earnings Release | 11/05/2024 |
| Earnings Report | - | Q4 2024 Earnings Release | 03/04/2025 |
| Earnings Report | - | Q1 2025 Earnings Release | 05/05/2025 |
Cassava Sciences Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | -0.430 USD | Q1 2024 Earnings Release | 05/10/2024 |
| Annual General Meeting | - | Annual General Meeting | 05/09/2024 |
Cassava Sciences Profile
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
5
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Cassava Sciences Shareholder
| Owner | in % |
|---|---|
| Freefloat | 93.60 |
| The Vanguard Group, Inc. | 4.85 |
| Vanguard Group, Inc. (Subfiler) | 4.67 |
| BlackRock Fund Advisors | 3.26 |
| Remi Barbier, MBA | 2.79 |
| BlackRock Institutional Trust Co. NA | 2.44 |
| Vanguard Total Stock Market ETF | 2.43 |
| Sanford R. Robertson, MBA | 2.37 |
| State Street Corp. | 2.28 |
| iShares Russell 2000 ETF | 1.93 |
| Geode Capital Management LLC | 1.88 |
| Vanguard Extended Market Index Fund | 1.23 |
| Gallacher Capital Management LLC | 1.22 |
| Cowen & Co. LLC | 1.04 |
| Richard Jon Barry | 0.98 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
